Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics to Develop miRNA Markers for Henry Ford's Brain Cancer Team

NEW YORK (GenomeWeb News) – Rosetta Genomics will develop microRNA-based diagnostics and prognostics for brain cancer with the Henry Ford Hospital, the company said today.
The company will work with researchers at the William and Karen Davidson Laboratory of Cell Signaling & Tumorigenes to conduct genome-wide association studies in search of miRNA biomarkers with predictive and diagnostic potential. Rosetta Genomics will use the results of those studies to perform miRNA analysis of formalin-fixed paraffin-embedded samples from the Henry Ford Hospital.
The Detroit-based hospital plans to use any diagnostic or prognostic biomarkers found in the research to manage disease staging and to predict patient response to treatment and the risk of recurrence of the disease.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.